Company intelligence / Profile preview
Senesco Technologies, Inc.
- Ownership
- Private
- Employees
- ~3
- Development stage
- Phase 1
Overview
Senesco Technologies was a clinical-stage biotech company focused on cancer therapeutics using proprietary gene regulation technology targeting the eIF5A pathway. Its lead candidate, SNS01-T, was in Phase I/II trials for multiple myeloma and other B-cell malignancies. The company merged with Fabrus in mid–2014 to combine its gene regulation approach with Fabrus’ novel monoclonal antibody discovery capabilities. Post-merger, the combined entity aimed to advance both platforms toward new oncology and immunology therapies.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Gene regulation therapeutics (e.g., eIF5A modulation)Monoclonal antibodies
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Senesco Technologies, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Senesco Technologies, Inc..